Ascendis Pharma A/S (NAS:ASND)
$ 121.12 -1.68 (-1.37%) Market Cap: 6.92 Bil Enterprise Value: 7.30 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

Ascendis Pharma A/S at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 17, 2020 / 07:30PM GMT
Release Date Price: $145.71 (+0.47%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Hello, I'd like to welcome you all once again to the Morgan Stanley 18th Annual Global Healthcare Conference. I'm one of the biotechnology analysts here. My name is David Lebowitz. Before we get into it, let me just read the requisite disclosures. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures.

(Operator Instructions)

Questions & Answers

David Neil Lebowitz
Morgan Stanley, Research Division - VP

And with that, I'm happy to welcome the next company into the virtual chat with me. We have from Ascendis Pharmaceuticals, CEO, Jan Mikkelsen; CFO, Scott Smith; and the Head of Development

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot